RFL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 22:06):

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel...

Stats
Šios dienos apimtis	15 210.00
Vidutinė apimtis	23 488.00
Rinkos kapitalizacija	40.57M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $0 ) 2024-06-11
Last Dividend	$0.0200 ( 2009-12-18 )
Next Dividend	$0 ( N/A )
P/E	17.05
ATR14	$0.0220 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share
2024-04-04	Jonas Howard S	Sell	348 259	Class B Common Stock, par value $.01 per share
2024-03-21	Conkling William	Buy	15 473	Class B Common Stock, par value $.01 per share
2024-03-21	Polinsky David	Sell	2 300	Class B Common Stock, par value $.01 per share
2024-01-30	Jonas Howard S	Buy	348 259	Class B Common Stock, par value $.01 per share

INSIDER POWER
52.49
Last 99 transactions
Buy: 18 593 840 \| Sell: 14 829 947

Rafael Holdings Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Rafael Holdings Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$279 000
Bruto pelnas:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2023
Pajamos:	$279 000
Bruto pelnas:	$201 000 (72.04 %)
EPS:	$-0.0806

FY	2022
Pajamos:	$410 000
Bruto pelnas:	$338 000 (82.44 %)
EPS:	$-6.31

FY	2021
Pajamos:	$3.97M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Rafael Holdings Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Rafael Holdings Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.90 - low (62.71%) | Divividend Growth Potential Score: 0.471 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2009-06-19
Last Dividend	$0.0200	2009-12-18
Next Dividend	$0	N/A
Payout Date	2009-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.0400	--
Avg. Dividend % Per Year	0.00%	--
Score	1.83	--
Div. Sustainability Score	4.90
Div.Growth Potential Score	0.471
Div. Directional Score	2.69	--

Next Divdend (Est)
(2024-10-14)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.83

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	7.77	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0201	1.200	9.33	10.00	[0 - 0.3]
returnOnEquityTTM	0.0213	1.500	-0.875	-1.312	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	23.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	22.86	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.19	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0160	-1.500	9.73	-10.00	[0 - 0.6]
interestCoverageTTM	-7.98	1.000	-4.07	-4.07	[3 - 30]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
freeCashFlowPerShareTTM	1.775	2.00	9.11	10.00	[0 - 20]
debtEquityRatioTTM	0.0162	-1.500	9.94	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.665	1.000	2.24	2.24	[0.2 - 0.8]
operatingProfitMarginTTM	-40.96	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.37	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00259	0.800	-3.32	-2.65	[0.5 - 2]
Total Score				4.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.85	1.000	8.20	0	[1 - 100]
returnOnEquityTTM	0.0213	2.50	-0.562	-1.312	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.775	2.00	9.41	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.314	2.00	-0.105	-0.209	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.313	1.500	-1.246	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-27.00	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.471

Rafael Holdings Inc

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.